Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 377-383

  Vijayaraghavan, Arthi ^a   Efrusy, Molly ^a   Lindeque, Gerhard ^b   Dreyer, Greta ^b   Santas, Christopher ^a  

^a McKesson   (United States)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cervical cancer; Cost effectiveness; Cytology; Health economics; Human immunodeficiency virus; Human papillomavirus

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SOUTH AFRICA; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; FEMALE; GENETIC TECHNIQUES; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MODELS, STATISTICAL; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SOUTH AFRICA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 58149522113     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.030     Document Type: Article

References (53)

1. Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 6 (2006) 135-140
2. Kuhn L., Denny L., Pollack A., Lorincz A., Richart R.M., and Wright T.C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J. Natl. Cancer Inst. 92 10 (2000) 818-825
3. Department of Health (South Africa). National HIV and syphilis antenatal sero-prevalence survey in South Africa. Pretoria (South Africa): National Department of Health; 2007 [cited 2007 Nov 29]. Available from: URL: http://www.doh.gov.za.
4. Ellerbrock T.V., Chiasson M.A., Bush T.J., Sun X., Sawo D., Brudney K., et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283 8 (2000) 1031-1037
5. Frisch M., Biggar R.J., and Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl. Cancer Inst. 92 18 (2000) 1500-1510
6. Goedert J.J., Coté T.R., Virgo P., Scoppa S.M., Kingma D.W., Gail M.H., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 (1998) 1833-1839
7. Department of Health (South Africa). National guideline on cervical cancer screening programme. Pretoria (South Africa): National Department of Health [cited 2007 Nov 29]. Available from: URL: http://www.doh.gov.za/docs/facts-f.html.
8. Arbyn M., Sasieni P., Meijer C.J.L.M., Clavel C., Koliopoulos G., and Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 S3 (2006) 78-89
9. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al., for the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357 16 (2007) 1579-1588
10. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, NewYork
11. Williamson A., Marais D., Passmore J., and Rybicki E. Human papillomavirus (HPV) infection in Southern Africa: prevalence, immunity, and vaccine prospects. IUBMB Life 53 (2002) 253-258
12. Ho G.Y.F., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338 7 (1998) 423-428
13. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J. Natl. Cancer Inst. 97 12 (2005) 888-895
14. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 285 23 (2001) 2995-3002
15. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151 12 (2000) 1158-1171
16. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis. 9 1 (2003) 37-48
17. NCDB, Commission on Cancer, ACoS/ACS. Survival Reports[online]. 2006 [cited 2006 Nov]. Available from: URL: http://web.facs.org/ncdbbmr/sas6/surv/GRAPHS/OY97S38XaT00000B.Html.
18. Wilkinson D., Karim S.S.A., Williams B., and Gouws E. High HIV incidence and prevalence among young women in rural South Africa: developing a cohort for intervention trials. J Acquir Immune Defic Syndr 23 5 (2000) 405-409
19. Vijayaraghavan A., Efrusy M.B., Mazonson P.D., Ebrahim O., Sanne I.M., and Santas C.C. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 46 1 (2007) 91-100
20. Sanders G.D., Bayoumi A.M., Sundaram V., Bilir S.P., Neukermans C.P., Rydzak C.E., et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med. 352 6 (2005) 570-585
21. Coetzee D., Hildebrand K., Boulle A., Maartens G., Louis F., Labatala V., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18 6 (2004) 887-895
22. Auvert B., Males S., Puren A., Taljaard D., Caraël M., and Williams B. Can highly active antiretroviral therapy reduce the spread of HIV?: a study in a township of South Africa. J Acquir Immune Defic Syndr 36 1 (2004) 613-621
23. Maartens G., Wood R., O'Keefe E., and Byrne C. Independent epidemics of heterosexual and homosexual HIV infection in South Africa-survival differences. QJM 90 7 (1997) 449-454
24. Minkoff H., Feldman J., DeHovitz J., Landesman S., and Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 178 5 (1998) 982-986
25. Sun X.W., Ellerbrock T.V., Lungu O., Chiasson M.A., Bush T.J., and Wright Jr. T.C. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet. Gynecol. 85 5 Pt 1 (1995) 680-686
26. Nappi L., Carriero C., Bettocchi S., Herrero J., Vimercati A., and Putignano G. Cervical squamous intraepithelial lesions of low-grade in HIV-infected women: recurrence, persistence, and progression, in treated and untreated women. Eur J Obstet Gynecol Reprod Biol 121 2 (2005) 226-232
27. Massad L.S., Evans C.T., Minkoff H., Watts D.H., Strickler H.D., Darragh T., et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet. Gynecol. 104 5 Pt 1 (2004) 1077-1085
28. Six C., Heard I., Bergeron C., Orth G., Poveda J.D., Zagury P., et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS 12 9 (1998) 1047-1056
29. Ratnam S., Franco E.L., and Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomark. Prev. 9 9 (2000) 945-951
30. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188 6 (2003) 1383-1392
31. Bigras G., and de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br. J. Cancer 93 5 (2005) 575-581
32. Benedet J.L., Bender H., Jones III H., Ngan H.Y., Pecorelli S., and for the FIGO Committee on Gynecologic Oncology. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int. J. Gynaecol. Obstet. 70 2 (2000) 209-262
33. Cook J., Dasbach E., Coplan P., Markson L., Yin D., Meibohm A., et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retrovir 15 6 (1999) 499-508
34. Minkoff H., Ahdieh L., Massad L.S., Anastos K., Watts D.H., Melnick S., et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 15 16 (2001) 2157-2164
35. Palefsky J.M. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr. Opin. Oncol. 15 5 (2003) 382-388
36. Heard I., Tassie J.M., Kazatchkine M.D., and Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 16 13 (2002) 1799-1802
37. Dorrington R., Bradshaw D., Budlender D., and Bourne D. The current state and future projections of the HIV/AIDS epidemic in South Africa. SADJ 57 11 (2002) 449-450
38. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al., Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
39. Woman's Health Advisory Board. South African HPV Advisory Board. Report of a meeting held at Kloofzicht on 12-14 August 2005.
40. Kulasingam S.L., Kim J.J., Lawrence W.F., Mandelblatt J.S., Myers E.R., Schiffman M., et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intra-epithelial lesion triage study (ALTS). J Natl Cancer Inst 98 2 (2006) 92-100
41. NCCN clinical practice guidelines in oncology: cervical cancer. V.2.2006.
42. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 15 (1999) 1144-1153
43. Cleary S, Boulle A, McIntyre D, Coetzee D. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Durban (South Africa): Health Systems Trust, Medecins Sans Frontieres, University of Cape Town; March 2004 [cited 2006 Nov 25]. Available from: URL: http://www.epi.uct.ac.za/.
44. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health (2001), World Health Organization, Geneva
45. International Monetary Fund South Africa. Staff report for the 2005 article IV consultation. Pretoria and Cape Town: International Monetary Fund; 2005 Aug 10 [cited 2006 Nov]. Available from: URL: http://www.finance.gov.za/publications/other/imf/2005/default.aspx.
46. The World Bank Group. South Africa data profile from World Development Indicators database, 2007 Apr [cited 2007 Dec]. Available from: URL: http://devdata.worldbank.org/external/CPProfile.asp?PTYPE=CP&CCODE=ZAF.
47. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahé C., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 20 (2005) 2158-2168
48. Goldie S.J., Kuhn L., Denny L., Pollack A., and Wright T.C. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 285 24 (2001) 3107-3115
49. Heard I., Schmitz V., Costagliola D., Orth G., and Kazatchkine M.D. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 12 12 (1998) 1459-1464
50. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine Suppl 1 (2008) A16-A23
51. Sankaranarayanan R., Chatterji R., Shastri S.S., Wesley R.S., Basu P., Mahe C., et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int. J. Cancer 112 (2004) 341-347
52. Hutubessy R., Chisholm D., and Edejer T.T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1 1 (2003) 8-21
53. Sculpher M.J., Pang F.S., Manca A., Drummond M.F., Golder S., Urdahl H., et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol. Assess. 8 49 (2004 Dec) 1-192 iii-iv